Surgery Partners Stock Alpha and Beta Analysis
| SGRY Stock | USD 24.39 0.18 0.74% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Surgery Partners. It also helps investors analyze the systematic and unsystematic risks associated with investing in Surgery Partners over a specified time horizon. Remember, high Surgery Partners' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Surgery Partners' market risk premium analysis include:
Beta 0.74 | Alpha 0.36 | Risk 3.18 | Sharpe Ratio 0.0912 | Expected Return 0.29 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Surgery |
Surgery Partners Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Surgery Partners market risk premium is the additional return an investor will receive from holding Surgery Partners long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Surgery Partners. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Surgery Partners' performance over market.| α | 0.36 | β | 0.74 |
Surgery Partners expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Surgery Partners' Buy-and-hold return. Our buy-and-hold chart shows how Surgery Partners performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Surgery Partners Market Price Analysis
Market price analysis indicators help investors to evaluate how Surgery Partners stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Surgery Partners shares will generate the highest return on investment. By understating and applying Surgery Partners stock market price indicators, traders can identify Surgery Partners position entry and exit signals to maximize returns.
Surgery Partners Return and Market Media
The median price of Surgery Partners for the period between Tue, Dec 24, 2024 and Mon, Mar 24, 2025 is 23.8 with a coefficient of variation of 9.56. The daily time series for the period is distributed with a sample standard deviation of 2.21, arithmetic mean of 23.12, and mean deviation of 2.05. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Insider Trading | 01/10/2025 |
2 | Bain Capital proposes to acquire remaining shares of Surgery Partners | 01/28/2025 |
3 | Disposition of 167 shares by Danielle Burkhalter of Surgery Partners at 25.68 subject to Rule 16b-3 | 02/04/2025 |
4 | Disposition of 26520 shares by Evans Jason Eric of Surgery Partners at 25.65 subject to Rule 16b-3 | 02/07/2025 |
5 | FMR LLC Reduces Stake in Surgery Partners Inc Analyzing the Implications | 02/12/2025 |
6 | Surgery Partners Inc Q4 2024 Earnings Report Preview What To Expect | 02/28/2025 |
7 | Surgery Partners, Inc. Announces Fourth Quarter and Full Year 2024 Results Sets 2025 Guidance | 03/03/2025 |
8 | Surgery Partners Inc Q4 2024 Earnings Call Highlights Record Revenue and Strategic Expansion | 03/04/2025 |
9 | Acquisition by Marissa Brittenham of 10084 shares of Surgery Partners at 23.8 subject to Rule 16b-3 | 03/06/2025 |
10 | Disposition of 3156 shares by Marissa Brittenham of Surgery Partners at 24.09 subject to Rule 16b-3 | 03/10/2025 |
11 | Acquisition by Marissa Brittenham of 2886 shares of Surgery Partners at 31.18 subject to Rule 16b-3 | 03/14/2025 |
About Surgery Partners Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Surgery or other stocks. Alpha measures the amount that position in Surgery Partners has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | |
| Dividend Yield | 0.001516 | 0.00144 |
| Price To Sales Ratio | 0.86 | 1.47 |
Surgery Partners Upcoming Company Events
As portrayed in its financial statements, the presentation of Surgery Partners' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Surgery Partners' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Surgery Partners' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Surgery Partners. Please utilize our Beneish M Score to check the likelihood of Surgery Partners' management manipulating its earnings.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 6th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Surgery Partners
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Surgery Stock Analysis
When running Surgery Partners' price analysis, check to measure Surgery Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Surgery Partners is operating at the current time. Most of Surgery Partners' value examination focuses on studying past and present price action to predict the probability of Surgery Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Surgery Partners' price. Additionally, you may evaluate how the addition of Surgery Partners to your portfolios can decrease your overall portfolio volatility.